Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Peldesine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Peldesine | DRUG | - |
Inclusion Criteria Patients must have: * Documented HIV infection. * CD4 cell count greater than or equal to 300 cells/mm3 on 3 occasions prior to protocol treatment. * Plasma viral load by Roche Amplicor HIV Monitor assay greater than or equal to 2,000 RNA copies/ml and less than or equal to 50,0...
Top 20 of 28 competitors
Peldesine is an investigational small molecule being studied for the treatment of HIV infections. It is being developed by BioCryst Pharmaceuticals, Inc. (BCRX) and is currently in Phase 1 clinical development. The drug is intended for use in patients with HIV, though it is not yet approved.
Peldesine is a small molecule developed by BioCryst Pharmaceuticals, Inc. (BCRX) for the treatment of HIV infections. It is currently in Phase 1 clinical development. The specific molecular target of Peldesine has not been disclosed in available information.
Peldesine is being developed by BioCryst Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol BCRX. The drug is an investigational small molecule intended for the treatment of HIV infections and is currently in Phase 1 clinical development.
Peldesine is in Phase 1 clinical development. It is an investigational small molecule being studied for the treatment of HIV infections. The drug is not yet approved and is still undergoing clinical trials to evaluate its safety and efficacy.
Peldesine has been studied in one clinical trial with the identifier NCT00002237, titled 'A Study of Peldesine (BCX-34) in HIV-Infected Patients'. This Phase 1 trial was completed in the United States and enrolled adult patients with HIV infections. The trial was uncontrolled and not randomized.
Yes, Peldesine is also known as BCX-34. The clinical trial NCT00002237, which studied Peldesine in HIV-infected patients, refers to the drug as Peldesine (BCX-34). This alternative name is used in the context of the drug's development by BioCryst Pharmaceuticals, Inc.